Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Metaclipse Therapeutics

Request full access

Delivering breakthrough technologies to treat cancer and infectious disease

Houston, United StatesFounded 2012Biotech & Life Sciences

About Metaclipse Therapeutics

Metaclipse Therapeutics Corporation is a clinical-stage biotechnology firm founded in 2011 and headquartered in Atlanta, Georgia. The company is focused on developing personalized immunotherapies for cancer and preventative vaccines for infectious diseases by utilizing its proprietary biological adjuvant technology. This platform works by anchoring cytokine and immunostimulatory protein adjuvants onto biological membranes, such as tumor-derived vesicles or virus-like particles, to enhance the body's immune response.

The company's lead cancer immunotherapy platform is named Membrex™. This is an autologous therapy, meaning it is created specifically for each patient. The process involves preparing membrane vesicles from a patient's own tumor tissue, which contains a unique array of patient-specific tumor antigens, and then modifying these vesicles with immunostimulatory proteins. When injected intradermally, Membrex™ is designed to deliver these adjuvants and antigens to the immune system simultaneously, aiming to generate a robust antitumor response. This approach shows potential to work in synergy with immune checkpoint inhibitors (ICI), possibly increasing response rates for cancers that are resistant to ICI therapy alone. Metaclipse received FDA clearance for Investigational New Drug (IND) applications to begin Phase 1 clinical trials for Membrex™ in triple-negative breast cancer (TNBC) in April 2023 and in head and neck squamous cell carcinoma (HNSCC) in August 2023. These trials, which are expected to enroll patients in 2025, will evaluate Membrex™ in combination with an approved ICI.

In addition to its cancer therapies, Metaclipse is developing the VaxRex™ vaccine platform for preventing infectious diseases. This platform uses virus-like particles (VLPs) modified with the company's biological adjuvants. The goal is to elicit strong humoral and cellular immunity, which could provide superior protection from viral infections, particularly for the elderly and immunocompromised individuals. The company has secured significant non-dilutive funding through grants and contracts, including awards from the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Cancer Prevention Research Institute of Texas (CPRIT). Notable funding includes a $6M CPRIT grant in November 2024 to support the HNSCC trial and a $355,000 NCI contract in September 2025 for preclinical development of an immunotherapy for nasopharyngeal carcinoma. Metaclipse's business model anticipates commercializing its products through licensing agreements with larger pharmaceutical companies after establishing safety and efficacy in clinical trials.

The leadership team includes co-founder and President Shaker J.C. Reddy and co-founder and Chief Scientific Officer Periasamy Selvaraj, Ph.D. Michael Coleman, Ph.D., serves as Senior Vice President of Strategy, bringing over 29 years of experience in biotech product development, including fundraising and successful IND filings.

Source: Dealroom company data

Metaclipse Therapeutics in the Houston ecosystem

Live from Dealroom

The Metaclipse Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • National Institutes of Health
  • National Cancer Institute (NCI)

Series A1 investor entered at this stage

  • Georgia Research Alliance
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Metaclipse Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Metaclipse Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.